Assessment of Adverse Events and Their Ability to Discriminate Response to Anti-PD-1/PD-L1 Antibody Immunotherapy
- PMID: 31675248
- DOI: 10.1200/JCO.19.01712
Assessment of Adverse Events and Their Ability to Discriminate Response to Anti-PD-1/PD-L1 Antibody Immunotherapy
Comment in
-
Reply to H. McLeod et al.J Clin Oncol. 2020 Jan 1;38(1):106. doi: 10.1200/JCO.19.02429. Epub 2019 Nov 1. J Clin Oncol. 2020. PMID: 31675249 No abstract available.
Comment on
-
Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody.J Clin Oncol. 2019 Oct 20;37(30):2730-2737. doi: 10.1200/JCO.19.00318. Epub 2019 May 22. J Clin Oncol. 2019. PMID: 31116675
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials